Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 3/20 | 0.86 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.86 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11244662 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL8677517 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL8609214 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL8978435 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL7706829 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL5200196 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL30060 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL9130809 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL10985730 | 1.00 | CA5A (0.86) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL23211674 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4229142-B1 | AN AQUEOUS POLYMER DISPERSION | WACKER CHEMIE AG (DE) | 2025-02-05 | — | — | EP | disclosed |
| US-20240110047-A1 | An Aqueous Polymer Dispersion | WACKER CHEMIE AG (DE) | 2024-04-04 | — | — | US | disclosed |
| EP-4229142-A1 | AN AQUEOUS POLYMER DISPERSION | Wacker Chemie AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022141163-A1 | AN AQUEOUS POLYMER DISPERSION | WACKER CHEMIE AG (DE) | 2022-07-07 | — | — | WO | disclosed |
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3856257-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856255-A1 | TREATMENT OF INFECTIONS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064844-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020064847-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| CN-109748405-A | A kind of oil field heat-resistance type Barium/Strontium Sulfate scale preventative and preparation method thereof | 中国石油大学(华东) | 2019-05-14 | — | — | CN | disclosed |
| CN-101809075-B | Stabilizer system for halogenated polymers | NABALTEC AG | 2013-04-24 | — | — | CN | disclosed |
| EP-2474583-A1 | BACK COATING COMPOSITION AND MIRROR | Asahi Glass Company, Limited (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-101809075-A | Stabilizer system for halogenated polymers | NABALTEC AG | 2010-08-18 | — | — | CN | disclosed |
| CN-1238761-A | benzamide aldehydes and their use as cysteine protease inhibitors | BASF AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| US-4168241-A | POWDERED CALCIUM OR BARIUM SULFATE, OTHER SOLID OR LIQUID LUBRICANTS | AICHI STEEL WORKS, LIMITED (JP) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | CA5A 1545/4885CA5B 1702/4885TSHR 1264/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | CA5A 675/4885CA5B 550/4885TSHR 493/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | CA5A 3345/4885CA5B 3123/4885TSHR 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.